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Background: Mesenchymal stem cells (MSCs) possess potent immunomodulatory properties and simultaneously
lack the ability to illicit immune responses. Hence, MSCs have emerged as a promising candidate for cellular
therapeutics for inflammatory diseases. Within the context of this study, we investigated whether human umbilical
cord-derived mesenchymal stem cells (UC-MSCs) could ameliorate lipopolysaccharide- (LPS-) induced acute lung
injury (ALI) in a rat model.
Methods: ALI was induced via injection of LPS. Rats were divided into three groups: (1) saline group(control),
(2) LPS group, and (3) MSC + LPS group. The rats were sacrificed at 6, 24, and 48 hours after injection. Serum,
bronchoalveolar lavage fluid (BALF), and lungs were collected for cytokine concentration measurements,
assessment of lung injury, and histology.
Results: UC-MSCs increased survival rate and suppressed LPS-induced increase of serum concentrations of
pro-inflammatory mediators TNF-α, IL-1β, and IL-6 without decreasing the level of anti-inflammatory cytokine IL-10.
The MSC + LPS group exhibited significant improvements in lung inflammation, injury, edema, lung wet/dry ratio,
protein concentration, and neutrophil counts in the BALF, as well as improved myeloperoxidase (MPO) activity in
the lung tissue. Furthermore, UC-MSCs decreased malondialdehyde (MDA) production and increased Heme
Oxygenase-1 (HO-1) protein production and activity in the lung tissue.
Conclusion: UC-MSCs noticeably increased the survival rate of rats suffering from LPS-induced lung injury and
significantly reduced systemic and pulmonary inflammation. Promoting anti-inflammatory homeostasis and
reducing oxidative stress might be the therapeutic basis of UC-MSCs.
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Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are common complications following
sepsis. Lipopolysaccharide (LPS) is considered to be an
important mediator of sepsis in response to gram-
negative bacteria. Hence, systemic administration of LPS
has been widely used as a clinically relevant model of
sepsis-related ALI [1]. Despite advances in supportive
care and ventilator management, mortality from ALI/* Correspondence: wfc.china@hotmail.com
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reproduction in any medium, provided the orARDS remains unacceptably high. Therefore, novel ef-
fective therapies are significantly needed.
Mesenchymal stem cells (MSCs) are cells of stromal
origin that can be isolated from multiple human tissues,
such as bone marrow (BM), adipose tissue, skeletal
muscle, synovium, gingiva, amniotic fluid, umbilical cord
blood, and the umbilical cord (UC). The ability of MSCs
to modulate the functions of cells associated with both
innate and adaptive immune systems makes them prom-
ising therapeutic candidates in the treatment to various
inflammatory diseases, including ALI/ARDS [2-4]. Re-
cently, several studies have suggested that the adminis-
tration of bone marrow- derived MSCs (BM-MSCs) in
animal models of ALI can reduce systemic inflammation,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, harvesting a patient’s BM to isolate and cul-
ture autologous MSCs cannot be done quickly enough
to provide emergency treatment for acute illnesses such
as ALI. Compared with the BM, the human umbilical
cord-derived mesenchymal stem cells (UC-MSCs) grow
more rapidly and can also secrete many types of factors
to create an immunosuppressive milieu [9,10], So UC
may be an ideal and practical source because of its ac-
cessibility, painless procurement from donors, lower risk
of viral contamination, and lack of any ethical concerns.
In this study, we investigate the therapeutic potential of
UC-MSCs in a LPS-induced rat model of ALI.
Methods
Animal care
Male Sprague–Dawley rats (weighing 240-280 g; from
Shandong University experimental animal center) were
used. Animals were maintained in the animal facility at
the Qilu Hospital of Shandong University. All experi-
mental protocols were approved by the Institutional Ani-
mal Care and Use Committee at Shandong University.
Generation and administration of UC-MSCs
UCs (n = 10, clinically normal pregnancies, approved by
the Qilu hospital’s human research ethics committee)
were excised and washed in a 0.1 mol/l phosphate buffer
(pH 7.4) to remove excess blood. The cords were dis-
sected and the blood vessels were removed. The re-
maining tissues were cut into small pieces (1–2 mm3)
and placed in plates with low-glucose Dulbecco-modified
Eagle medium (L-DMEM) (Gibco-BRL, Grand Island,
NY), supplemented with 10% fetal bovine serum (FBS,
Gibco-BRL), 2 ng/mL vascular endothelial growth factor
(VEGF; R&D Systems, Minneapolis, MN), 2 ng/mL epi-
dermal growth factor (EGF; R&D Systems), 2 ng/mL
fibroblast growth factor (FGF; R&D Systems), 100 U/ml
penicillin, and 100 μg/ml streptomycin (Gibco-BRL).
Cultures were maintained at 37°C in a humidified at-
mosphere with 5% CO2. The media were changed every
3–4 d. Adherent cells proliferated from individual ex-
planted tissues 7–12 d after initiating incubation. At this
time, the small tissue pieces were removed from the cul-
ture and the adherent fibroblast-like cells were cultured
to confluence, which subsequently took 2–3 weeks in
culture. The cells were then trypsinized using 0.25%
trypsin (Gibco-BRL) and passaged at 1 × 104 cells/cm2 in
the medium described above. The cells were used after
five or more passages.
Cell surface antigen phenotyping
Fifth- to seventh-passage cells were collected and treated
with 0.25% trypsin. The cells were stained with either
fluorescein isothiocyanate-conjugated or phycoerythrin-conjugated monoclonal antibodies in 100 μl phosphate
buffers for 15 min at room temperature, as suggested by
the manufacturer. The antibodies used were against hu-
man antigens CD29, CD34, CD44, CD45, CD73, CD90,
CD105, and CD106 (SeroTec, Raleigh, NC). Cells were
analyzed using flow cytometry (Cytometer 1.0, Cyto-
micsTM FC500, Beckman Coulter). Positive cells were
counted and compared to the signal of corresponding
immunoglobulin isotypes.
Differentiation capacity
To investigate the differentiation potential of the
fibroblast-like cells, P4 cells were cultured under condi-
tions appropriate for inducing the differentiation of each
lineage. Cells were seeded at a density of 2x104 cells/cm2
and the differentiation media were changed every 3–4 d.
The osteogenic differentiation medium consisted of L-
DMEM supplemented with 10% FBS, 0.1 μM dexa-
methasone, 50 mM β-glycerol phosphate, and 0.2 mM
ascorbic acid (Sigma-Aldrich, St. Louis, MO). The adipo-
genic differentiation medium consisted of high-glucose
DMEM supplemented with 0.25 mM 3-isobutyl-1-
methylxanthine, 0.1 μM dexamethasone, 0.1 mM indo-
methacin (Sigma-Aldrich), 6.25 μg/ml insulin (PeproTech,
UK), and 10% FBS (Gibco-BRL). Cells kept in the normal
growth medium served as the control.
Experimental design and LPS-induced lung injury
Briefly, rats were randomly assigned into one of three
groups: saline control group, LPS group, and MSC+LPS
group (n = 15 for each group). ALI was induced by the
injection of LPS from E.coli O111:B4 (Sigma-Aldrich)
(10 mg/kg intraperitoneal) and left untreated for 1 h,
after which rats were given either MSCs [5 × 105 cells in
300 μl of normal saline (NS)] or 300 μl of NS via injec-
tion into the tail vein. Additional experiments were done
in which a human fibroblast cell line, MRC-5, was used
as additional control (5 × 105 cells in 300 μl of NS).
Three to five rats from each group were anesthetized
and sacrificed at each time point (6, 24, and 48 hours
post-injection of LPS) for cytokine concentration mea-
surements, assessment of lung injury, and histology.
Four groups of rats (n = 20 per group) were used for
survival study. LPS, UCMSCs and fibroblast cells were
given as described above. The rats were then allowed to
recover. Mortality was recorded up to 48 hours after the
treatment.
Collection of bronchoalveolar lavage fluid (BALF) and
tissue samples
Rats were euthanized and their thoraxes were opened by
a midline thoracotomy. 3 ml of blood was then collected
from the heart and centrifuged at 2000 rpm at 4°C for
10 min. The serum was collected and stored at −80°C
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was isolated and the right bronchial tube was ligated.
BALF was obtained by placing a 20-gauge catheter into
the trachea through which 3 ml of cold PBS was flushed
back and forth three times. The BALF was centrifuged
at 3000 rpm for 20 min at 4°C. The resulting cell pellet
was used to determine the total cell count through the
use of a counter (Beckman Coulter). A cell smear was
made using Wright-Giemsa staining to confirm the neu-
trophil percentage. Protein concentration of the cell-free
BALF from all groups was measured via Bio-Rad protein
assay kit and used as an indication of endothelial and
epithelial permeability. The right middle lung lobes were
stored in liquid nitrogen at −80°C until subsequent ana-
lysis. The right upper lobes were used for quantifying
the magnitude of pulmonary edema. The right lower
lobes were used for histological evaluation.
Lung histopathology
Paraffin-embedded lungs were cut into 5 μm thick sec-
tions and subsequently stained with hematoxylin and
eosin for histological analysis. A pathologist blindly
scored each lung injury using the following four categor-
ies: alveolar congestion, hemorrhage, neutrophil infiltra-
tion into the airspace or vessel wall, and thickness of
alveolar wall/hyaline membrane formation. Each cat-
egory was graded on a 0- to 4-point scale: 0 = no injury;
1 = injury up to 25% of the field; 2 = injury up to 50% of
the field; 3 = injury up to 75% of the field; and 4 = diffuse
injury [5].
Wet-dry analysis
The right upper lobes of lungs were placed into
previously-weighed microcentrifuge tubes and weighed.
Lungs were then desiccated under a vacuum overnight
at 80°C and weighed again. The wet lung mass was
divided by the dry lung mass to give the wet-dry ratio.
Cytokine measurement in serum
TNF-α, IL-1β, IL-6, and IL-10 serum levels of the rats
was measured by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions
(R&D Systems).
Measurement of myeloperoxidase (MPO) activity
To quantify neutrophil infiltration, MPO activity in
the homogenized lung tissues was measured as previ-
ously described by Jin et al. [11]. After thawing, lung
tissues were homogenized in a phosphate buffer (20 mM,
pH 7.4) and centrifuged at 30,000 g for 30 min. The
pellet was then resuspended in a potassium phosphate
buffer (50 mM, pH 6.0) with 0.5% hexadecyltrimethyl
ammonium bromide. Samples were then centrifuged at
20,000 g for 15 min at 4°C. The supernatants wereisolated. After addition of 0.167 mg/mL O-dianisidine
hydrochloride and 0.0005% hydrogen peroxide to each
sample, their absorbances were measured via spectro-
photometry at 460 nm. Results were expressed as units
of MPO per gram of wet tissue.
Malondialdehyde (MDA) analysis
MDA levels in the lung tissue were used as an indicator
of lipid peroxidation and were measured in tissue hom-
ogenate by the method detailed previously by Kurutas
et al. [12]. In brief, 0.2 ml of the lung homogenate was
mixed with 0.2 ml of 8.1% sodium dodecyl sulfate,
1.5 ml of 20% acetic acid, and 1.5 ml of 0.8% aqueous
solution of thio-barbituric acid. The pH of the mixture
was adjusted to 3.5 and the volume was brought up to
4.0 ml using distilled water. This mixture was then kept
in a boiling water bath for 1 h. After cooling under tap
water, 1.0 mL of distilled water and 5.0 ml of a mixture
of n-butanol and pyridine (15:1, v/v) was added. The re-
sulting mixture was shaken vigorously. The absorbance
of the organic layer was measured via spectrophotom-
etry at 532 nm. MDA level was expressed as nmol/mg
protein.
Heme oxygenase-1 (HO-1) activity assay
HO-1 activity was determined by the spectrophotometry
of bilirubin formation, as described previously [13].
Briefly, the reaction mixture consisted of 200 μl of lung
supernatant, 50 μl of liver cytosol, 20 μl of 1 mmol/L
heme b solution, 200 μl of 2.75 mmol/L β-NADPH solu-
tion, and 530 μl of 2 mmol/L MgCl2 100 mmol/L phos-
phate buffer (pH 7.4). The samples were incubated in a
37°C water bath in the dark for 1 hour. The reaction was
stopped by placing the samples on ice. An NADPH-free
reaction mixture was used as a baseline to which the
measured concentrations were compared. The absorb-
ance of the samples was measured by a UV/visible spec-
trophotometer ultrospec 2000 (Pharmacia Biotech) at
464 nm and 530 nm. The amount of bilirubin formed
was calculated from the difference in absorbance mea-
surements at 464 nm and 530 nm. The values were
expressed as picomoles of bilirubin formed per milli-
gram of protein per hour.
Western blotting for HO-1
Lung homogenates were evaluated for HO-1 protein ex-
pression by Western blotting with primary antibodies to
HO-1 (Santa Cruz Biotechnology, Santa Cruz, CA).
Western blot analysis was performed as described previ-
ously [14].
Statistical analysis
All data are presented as mean± standard deviation.
They were compared via ANOVA followed by a Student’s
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analyzed by the Kaplan-Meier method and compared via
the log-rank test. Differences between values were con-
sidered significant at P < 0.05.
Results
Characterization of the UC-MSCs and their differentiation
capacity
After several passages, adherent cells from UC could
form a monolayer of typical fibroblastic cells (Figures 1A).
Flow cytometry results showed that UC-derived cells
shared most of their immunophenotype with mesenchy-
mal stem cells, including positive expression for stromal
markers (CD29, CD44, CD73, CD90, CD105, and CD106),
but negative expression for hematopoietic markers (CD34
and CD45) (Figure 1E).
MSC differentiation was assessed using P4 cells. When
induced to differentiate under osteogenic conditions,
MSC congregation increased with increasing induction
time and formed a mineralized matrix, as confirmed by
alizarin red staining (Figure 1B). Most of the MSC-likeFigure 1 UC-derived MSC-like cells in passaged cultures. (A) H&E stain
by (B) the formation of mineralized matrix shown by alizarin red staining a
noted by the presence of broadened morphology and formation of lipid v
Immunophenotype of UC-derived MSC-like cells.cells became alkaline-phosphatase-positive by the end of
14 d (Figure 1C). No mineralized matrix was observed
in the control cells kept in the normal growth medium.
The spindle shape of the MSCs flattened and broadened
after 1 wk of adipogenic induction. Small oil droplets
gradually appeared in the cytoplasm. By the end of the
second week, almost all cells contained numerous oil-
red-O-positive lipid droplets (Figure 1D). The control
cells maintained in the regular growth medium did not
stain positive for oil red O.
UC-MSCs treatment attenuates systemic inflammation
associated with LPS
Animals receiving LPS showed physical signs of systemic
illness including lethargy, piloerection, and diarrhea.
Serum was collected at 6, 24, and 48 hours to evaluate
levels of TNF-α, IL-1β, IL-6, and IL-10 (Figure 2). LPS
caused a significant acute systemic inflammatory re-
sponse as evidenced by the increased serum concentra-
tions of the pro-inflammatory mediators TNF-α, IL-1β,
and IL-6. The response of pro-inflammatory cytokinesing of UC-derived MSC-like cells. Osteogenic differentiation as indicated
nd (C) alkaline phosphatase expression. Adipocytic differentiation was
acuoles (D) (positive oil-red O staining). Scale bars = 80 μm. (E)
Figure 2 (A-C) LPS caused a significant acute systemic inflammatory response as early as 6 hours. Administration of UC-MSCs reduced
pro-inflammatory cytokines at each time point. (D) LPS also caused an increase of anti-inflammatory cytokine IL-10, but this change was not
altered by intravenous administration of UC-MSCs (*, p < 0.05 compared with healthy controls; #, p < 0.05 comparing LPS plus UC-MSCs with LPS
alone).
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decreased gradually at the 24 and 48 hour time-points.
The presence of UC-MSCs reduced the increase of these
three pro-inflammatory cytokines at each of the time
point. LPS also caused an increase of the serum concen-
tration of the anti-inflammatory cytokine IL-10. This
change in IL-10 concentration was not altered by intra-
venous administration of UC-MSCs.
UC-MSCs prevents LPS-induced ALI
Histology
Six hours after intraperitoneal injection of LPS, the ca-
pillaries in the lung tissue expanded and became con-
gested by a significant increase in neutrophils. These
events peaked at the 24 hour time-point. In addition, the
lung septae obviously thickened and did not show any
improvement 48 hours later. MSC+LPS rats also dis-
played moderate injury, but the severity was significantly
less compared to the LPS group at all three time points
(Figure 3A). To quantify the effect of UC-MSCs on ALI,
we used a 5-level score evaluation system. As shown in
Figure 3B, the lung injury score was significantly lower
in the MSC+LPS group at all time points. In contrast,
rats given injection of human fibroblast cell line, MRC-5,
had no improvement in lung injury (Figure 3A and 3B).
Wet-dry ratio and BALF protein concentration
The lung wet-dry weight ratio was significantly higher at
24 h after LPS administration and slightly reduced at48 h. However, UC-MSCs attenuated this change signif-
icantly (Figure 4A). In terms of endothelial and epithelial
permeability, BALF protein concentration increased
quickly after LPS injection and reached its peak at
24 hours. The MSC+LPS group exhibited relatively
lower protein concentrations, but this difference was not
statistically significant (Figure 4B).
Neutrophil infiltration in the lungs
LPS caused significant increase of neutrophil counts in
the BALF and MPO activity in the lung tissue at 24 and
48 h. These increases were reduced in the MSC+LPS
group (Figures 5A and 5B).
MSC transplantation inhibited LPS-induced oxidative stress
in lung parenchyma
Lung MDA levels increased markedly in the LPS group
compared with the control group at each time point,
whereas the increase was significantly attenuated in the
MSC+LPS group as shown in Figure 6A. In the control
group, the lung expression of HO-1 was very weak at
24 h. However, HO-1 expression was found to be mark-
edly enhanced in the LPS group and even higher in the
MSC+LPS group (Figure 6C). A similar observation was
made in terms of lung HO-1 activity (Figure 6B).
MSCs improved survival rates
Rats that received UC-MSCs had significantly higher
rate of survival versus the LPS group (87% vs. 60%;
Figure 3 (A) Histological analysis indicated LPS injection caused capillary expansion and congestion, as well as neutrophil infiltration
into the lung tissue. In addition, lung septae was noticeably thickened. Administration of UC-MSCs improved the lung injury at all time points.
(B) Lung injury score decreased significantly in the MSC + LPS group at all time points (*, p < 0.05 compared with healthy controls; #, p < 0.05
comparing LPS plus UC-MSCs with LPS alone.). Fibroblast injections have no effect on improvement of both pathological morphology and lung
injury score.
Figure 4 (A) Injection of UC-MSCs reduced pulmonary edema induced by LPS. Pulmonary edema was measured as the wet-dry ratio. (B):
BALF protein concentration significantly increased after LPS injection and reached its peak at 24 h, while UC-MSCs caused a non-satistically
significant decrease in the protein concentration. (*, p < 0.05 compared with healthy controls; #, p < 0.05 comparing LPS plus UC-MSCs with
LPS alone.).
Li et al. Journal of Inflammation 2012, 9:33 Page 6 of 11
http://www.journal-inflammation.com/content/9/1/33
Figure 5 (A) BALF neutrophil counts and (B) lung MPO activity. Neutrophil counts and lung tissue MPO activity were significantly higher in
the LPS group compared to the control group. Treatment with UC-MSCs significantly reduced the LPS-induced increase in BALF neutrophil
counts and lung MPO activity at 24 and 48 hours (*, p < 0.05 compared with healthy controls; #, p < 0.05 comparing LPS plus UC-MSCs with
LPS alone).
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improvement in survival compared with LPS group.
Treatment with UC-MSCs increased the survival rate
about 20% over 48 hours. p < 0.05.Discussion
As shown in several animal studies over the last few
years, BM-MSCs can alleviate LPS-induced acute lung
injury (ALI) by restoring lung function and increasing
survival rate via its anti-inflammation, anti-apoptosis,
and immune regulation properties. They thus may pro-
vide a new therapy for ALI. However, since BM-MSCs
decrease in number and proliferative capacity as donor
age increases and are vulnerable to infection during pre-
paration [15], it is necessary to find a new MSC source.
MSCs can be isolated from almost any tissue and
organ. Its low immunogenicity and advantages in im-
mune regulation are independent from the tissue source
[16,17]. Compared to BM-MSCs, UC-MSCs have more
advantages. UC-MSCs are easier to access and collect,
are more secure and abundant, and exhibit higher prolif-
eration rates [18,19]. It has been reported that UC-
MSCs showed great capacity for immunomodulation,
anti-inflammation, and anti-oxidation in treating lupus
[20], colitis [21], bleomycin-induced pulmonary fibrosis
[22] and arthritis [23]. However, little is known about
UC-MSCs in the treatment of ALI.
Data from this study demonstrated that intravenous
injection of UC-MSCs 1 hour after endotoxin injury
clearly improved the survival rate of the rat model, sig-
nificantly reduced the systemic and pulmonary inflam-
mation, and ameliorated the pathological conditions of
lung injury. The improvement of anti-inflammatory
homeostasis and decrease of oxidative stress could be
the key mechanisms of the treatment.Severe endotoxemia may activate inflammatory cells
and cause inflammatory reactions that lead to tissue and
organ injury, dysfunction, and even death. Lung tissue is
one of the most vulnerable tissues to endotoxemia. LPS
can cause ALI and further develop to acute respiratory
distress syndrome (ARDS) [24,25]. We created an endo-
toxemia rat model via the use of intraperitoneal injec-
tion of LPS, simulating sepsis-related lung injury, in
order to observe the effect of UC-MSCs on acute lung
injury. Experimental results showed that the rats exhibited
varying degrees of lung tissue hyperemia, hemorrhage,
alveolar septal thickening, infiltration of inflammatory
cells, and neutrophil accumulation, which are all path-
ological changes associated with acute lung injury. This
indicated the model was successful.
Transient inflammatory reactions are used to protect
the body against infection and toxin invasion. ALI is an
uncontrollable pulmonary inflammation caused by large
amounts of inflammatory cells and cytokines. Under the
effects of LPS, lung macrophages and neutrophils pro-
duce pro-inflammatory cytokines, like TNF-α and IL-1β,
triggering the inflammatory reaction cascade [26-28]. In
this study, the plasma concentrations of TNF-α, IL-1β,
and IL-6 significantly increased 6 hours after intra-
peritoneal injection of LPS. When UC-MSCs were admi-
nistrated 1 hour after LPS-induced injury, the plasma
concentration of pro-inflammatory cytokines and lung
inflammation decreased significantly. In vitro studies
showed that BM-MSCs can reduce TNF-α and IL-6 se-
cretion by lung macrophages via paracrine pathway or
direct contact with host cells [5,6]. The difference be-
tween ALI/ARDS and normal inflammatory responses
lies in the imbalance between inflammatory and anti-
inflammatory activity, of which IL-10 is one of the most
important anti-inflammatory cytokines. It has been re-
ported that BM-MSCs may markedly increase the IL-10
Figure 6 (A) MDA levels were significantly increased in
LPS-treated rats compared to the control group. This increase
was significantly reduced at 24 and 48 hours by treatment with
UC-MSCs. (B) Activity of HO-1 in the lungs of LPS-treated rats at
24 hours. (C) Expression of HO-1 as measured by Western blotting
analysis at 24 hours. LPS induced HO-1 protein expression and
stimulated HO-1 activity in the lung tissues. Treatment with
UC-MSCs further increased the expression and activity of HO-1
(*, p < 0.05 compared with healthy controls; #, p < 0.05 comparing
LPS plus UC-MSCs with LPS alone).
Figure 7 The survival rate of the LPS + MSC group over
48 hours is significantly higher than that of the LPS group
(87% vs 60%; * p< 0.05). UC-MSCs treatment improved survival
rates at all time-points.
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ALI rats. In this study, the plasma IL-10 level rose mark-
edly after intraperitoneal injection of LPS, while it didn’t
change after UC-MSCs administration, which differs
from other studies [5,29]. UC-MSCs administration
clearly inhibits the production of pro-inflammatory cyto-
kines TNF-α, IL-1β, and IL-6, and does not suppress the
IL-10 level. Thus, it improves the homeostasis of the
cytokine network and thus the balance between the in-
flammatory and anti-inflammatory reactions associated
with ALI.
Neutrophil accumulation in the lung and pulmonary
edema are two other important attributes of ALI.Neutrophils accumulated in the lung may cause mech-
anical obstruction of the pulmonary capillary bed, lead-
ing to microcirculation disturbance. In addition, the
metabolic products of stranded and activated neutro-
phils can destroy the alveolar capillary barrier and in-
crease its permeability. This causes protein-rich fluid to
leak into the alveolar lumen and interstitial lung, which
results in pulmonary edema [24,30]. As a proteinase
highly expressed in neutrophils, MPO is the major indi-
cator of neutrophil infiltration [31]. Compared to the
LPS-injected rats, rats intravenously infused with UC-
MSCs clearly reduced the amount of neutrophils in
bronchoalveolar lavage fluid and MPO activity in lung
tissues. Moreover, the lung wet-dry ratio results showed
that the pulmonary edema improved. MSCs can produce
several epithelial-specific growth factors, such as soluble
paracrine factors ANG1, KGF, and HGF, which are im-
portant in ameliorating the increased lung permeability
induced by LPS [32]. MSCs may also reduce the perme-
ability of human umbilical vein endothelial cells by using
VEGF to stimulate the up-regulation of vascular endo-
thelial cell cadherin and β-catenin [33]. Although the
mechanisms of pulmonary edema and neutrophil accu-
mulation are different, the two events may not occur
simultaneously [34]. Our study showed that both of
these events might participate in the process by which
MSCs modulate LPS-induced injury.
Oxidative stress is a sign of inflammation. Previous
studies on various lung inflammation diseases confirmed
that oxidative stress and oxidative damage are closely
related to the development and severity of ALI/ARDS
[35-37]. During ALI/ARDS, the main sources of reactive
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macrophages. ROS-induced ALI occurs on a pathway
parallel to the inflammatory reaction. MDA is the main
product of lipid peroxidation and most tests define the
degree of oxidative damage of the body by determining
the amount of MDA [38]. This study shows that UC-
MSCs significantly reduced the amount of MDA in the
damaged lung tissue, indicating the redox environment
in the lung improved. HO-1 is the most easily induced
antioxidative enzyme in vivo, with strong antioxidative
stress and cytoprotective effects [39]. UC-MSCs signifi-
cantly increased the synthesis of HO-1 while reducing
the amount of MDA in the lung, indicating that antioxi-
dative stress is an important factor that is addressed
when treating endotoxin-induced lung injury with UC-
MSCs. Several in vitro and in vivo studies proved that
MSCs can potentially regulate the redox environment.
Iyer et al. found that BM-MSCs can maintain the
steady-state of cysteine (Cys) and glutathione (GSH) in
plasma during endotoxemia and reduce the oxidation of
the Cys and GSH redox system [40]. Sun et al. con-
firmed that the antioxidation effect of adipose tissue
derived-MSCs play an important role in ameliorating
lung ischemia-reperfusion injuries [41].
To date, the mechanisms responsible for the thera-
peutic effects of MSCs on ALI have not been completely
understood. The multi-potent property and the ability to
secrete multiple paracrine factors are the potential
mechanisms underlying their therapeutic use. Due to the
low engraftment rates of <1% in lung injury models
[8,42], recent studies consider the capacity to secrete
paracrine soluble factors to be the major beneficial role.
Through cell-contact-dependent and -independent
mechanisms, MSCs secrete or induce multiple paracrine
factors such as transforming growth factor-β, tumor necro-
sis factor α induced protein, IL-10, indoleamine 2, 3-dioxy-
genase, PGE2 to mediate immunomodulation, and
keratinocyte growth factor, Angiopoietin-1 to regulate lung
endothelial permeability [43]. Although we had not mea-
sured these factors except IL-10, we found reducing oxida-
tive stress might be one of the therapeutic bases of UC-
MSCs, further study is needed to understand the anti-
oxidative mechanism of these cells. A recent study demon-
strated that intrapulmonary delivery of human UC-MSCs
attenuates acute lung injury by expanding CD4 + CD25+
Forkhead Boxp3(FOXP3) + regulatory T Cells, despite
different cytokines detected, they also confirmed the bal-
ance effect of UC-MSCs on pro- and anti- inflammatory
cytokines in ALI [44].
In this study, we applied human UC-MSCs to LPS-
induced lung injury in a rat model. The xenogenic cell
transplantation showed good therapeutic effects. Deuse
et al. found that human umbilical cord lining mesenchy-
mal stem cells had significantly lower HLA class Iexpression, higher production of tolerogenic TGF-β and
IL-10, and showed significantly faster proliferation com-
paring with adult bone marrow MSCs from patients
>65 years of age [45]. Because UC-MSCs have lower im-
munogenicity than adult BM-MSCs, human UC-MSCs
can survive for a longer period of time in mice, and a
single injection does not elicit a host immune response
[46]. Additionally, a one-year long continuous study of
treating Parkinson’s disease in rats with human UC-
MSCs confirmed its safety and efficacy [47]. Chen et al.
found that UC-MSCs had higher endothelial differenti-
ation potential than BM-MSCs. Therefore, UC-MSCs
are more favorable choice than BM-MSCs for neovascu-
larization of engineered tissues [48]. These studies pro-
vide a foundation for potentially treating human diseases
using UC-MSCs in future.
Conclusions
In summary, this study demonstrated that intravenous
injection of UC-MSCs clearly increased the survival rate
of rats suffering from LPS-induced lung injuries and sig-
nificantly reduced systemic and pulmonary inflamma-
tion. Promoting anti-inflammatory homeostasis and
reducing oxidative stress may be the therapeutic basis of
UC-MSCs for this disease model.
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